Optimum selection criteria for secondary cytoreductive surgery in patients with recurrent epithelial ovarian cancer: A multicenter study from the Gynecologic Oncology Research Investigators coLLaborAtion group (GORILLA-3001)
- Authors
- Son, Joo-Hyuk; Kong, Tae-Wook; Park, Soo Jin; Lee, Eun Ji; Kim, Hee Seung; Kim, Nam Kyeong; Kim, Yeorae; Hwang, Woo Yeon; Suh, Dong Hoon; Kim, Tae Hun; Yang, Eun Jung; Shim, Seung-Hyuk; Chang, Suk-Joon
- Issue Date
- Sep-2023
- Publisher
- John Wiley and Sons Inc
- Keywords
- patient selection; recurrent ovarian cancer; secondary cytoreductive surgery
- Citation
- Journal of Surgical Oncology, v.128, no.4, pp 645 - 652
- Pages
- 8
- Journal Title
- Journal of Surgical Oncology
- Volume
- 128
- Number
- 4
- Start Page
- 645
- End Page
- 652
- URI
- https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/74164
- DOI
- 10.1002/jso.27303
- ISSN
- 0022-4790
1096-9098
- Abstract
- Background: To identify those most likely to benefit from secondary cytoreductive surgery (SCS), we evaluated the survival outcomes and factors predictive of prognosis in patients with recurrent ovarian cancer. Methods: We retrospectively reviewed the medical records of patients with recurrent ovarian cancer treated at five high-volume Korean hospitals between 2010 and 2021. Recurrence characteristics, treatment methods, and potential predictors of survival were compared between the chemotherapy and surgery groups. Results: Among all 670 patients, 88.1% had initial stage III/IV disease, and 215 (32.1%) underwent SCS. Among patients who underwent SCS, only those who achieved complete resection exhibited improved survival. Even in patients with residual disease < 1 cm after SCS, we observed no significant survival benefit (p = 0.942). In the multivariate Cox analysis, residual disease at primary surgery, progression-free interval, recurrence sites (≤3 regions or limited carcinomatosis), ascites, and SCS were significant predictors of survival. Meanwhile, the only factor predictive of complete resection after SCS was recurrence sites (p < 0.001). Conclusions: The benefits of SCS appear to be exclusive to cases of complete resection. We propose limited regional platinum-sensitive recurrence (≤3 regions or limited carcinomatosis) without ascites as the optimum selection criteria for SCS. © 2023 Wiley Periodicals LLC.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - ETC > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/74164)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.